Safety and Efficacy Study of Once and Twice Daily Doses of MCC-135 in Subjects With Congestive Heart Failure.

Completed · Phase 2 · Has a placebo group

Conditions studied: Congestive Heart Failure

In brief

The purpose of this study is to determine the effect of two different doses of MCC-135, once daily (QD) or twice daily (BID), on the disease state and the quality of life in subjects with congestive heart failure.

Key facts

Study ID
NCT00050076
Run by
Takeda
People needed
204
Starts
2002-08-01
Expected to finish
2003-08-01
Last updated by the study team
2012-02-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.